Loading stock data…
FMS
$22.70-0.54 (-2.32%)
Market ClosedLast close Jun 29
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius Medical Care AG in the Healthcare sector is trading at $22.70 with a market capitalization of $12.7B. Wall Street consensus targets $25.41 (6 analysts), implying a +12.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $28.87, remaining 0.4% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +12.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.61B↓ | $5.07B↑ | $4.88B↑ | $4.79B↓ | $4.88B |
| Gross Profit | $1.18B↓ | $1.39B↑ | $1.24B↑ | $1.21B↑ | $1.18B |
| Operating Income | $375.56M↓ | $548.98M↑ | $501.72M↑ | $394.40M↑ | $381.73M |
| Net Income | $117.53M↓ | $327.08M↑ | $274.80M↑ | $225.27M↑ | $151.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a ne...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.13%
Volume
Today's trading volume
810,289
Recent News
Fresenius Medical Care (XTRA:FME) Faces EU Setback After TAVNEOS Revocation Recommendation
The European Medicines Agency committee has recommended revoking the EU marketing authorisation for TAVNEOS®. This decision affects Fresenius Medical Care’s (XTRA:FME) treatment portfolio for patients in the European Union. The recommendation introduces uncertainty for clinicians and patients relying on this therapy within the EU. Fresenius Medical Care is a global provider of dialysis products and services, so any change in its therapy portfolio can matter for both its operations and...
Fresenius Medical Care dips after US proposes lower dialysis reimbursement rate
Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.